Amylyx Pharmaceuticals, Inc.
AMLXHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframePart of the healthcare sector, Amylyx Pharmaceuticals, Inc. (AMLX) is listed under Drug Manufacturers - Specialty & Generic. Valued at $3.78B, AMLX is a mid-cap name in its sector. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism.
Market Cap
$3.78B
Beta
-0.12
P/E (TTM)
—
P/E (Fwd)
-29.34
EPS (TTM)
$-1.41
EPS (Fwd)
$-1.15
ROE
-74.7%
ROA
-44.1%
Cash
$250.8M
Total Debt
$5.3M
Free CF
-$77.3M
52W Change
188.3%
Annual Financials
Cash vs Debt
Where AMLX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, AMLX finished 94.64% above its 150-day moving average ($17.72) and 107.02% above its 200-day moving average ($16.66). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AMLX overbought or oversold?
At the September 3, 2026 close, AMLX's RSI(14) was 73.0, in overbought territory (above 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $250.8M in cash and $5.3M in debt, AMLX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$77.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -74.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $22.2M (2022) to $0 (2025), a 100% decline worth watching.
With a beta below 0.7, Amylyx Pharmaceuticals, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, AMLX has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing AMLX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.